What is Korio?
Korio operates as a specialized software provider dedicated to the clinical trial ecosystem. Its core platform is engineered to address the inefficiencies inherent in traditional RTSM workflows, which have historically been characterized by manual intervention and high error rates. By embedding the expertise of industry subject matter experts directly into its software architecture, Korio enables clinical research organizations to achieve more predictable outcomes within significantly compressed timelines.
The company's market position is defined by its ability to bridge the gap between complex regulatory requirements and agile software delivery. By focusing on the intersection of clinical operations and digital transformation, Korio is effectively challenging the status quo of established RTSM providers, offering a scalable solution that supports the entire lifecycle of a clinical trial from initiation to final data submission.
How much funding has Korio raised?
Korio has raised a total of $6.8M across 1 funding round:
Other Financing Round
$6.8M
Other Financing Round (2023): $6.8M with participation from Boston Millennia Partners and Excelerate Health Ventures
Key Investors in Korio
Boston Millennia Partners
Boston Millennia Partners provides private equity financing to high growth companies in the healthcare and life sciences industry, leveraging decades of operational and financial expertise.
Excelerate Health Ventures
Excelerate Health Ventures is a venture capital firm focused on investing in digital healthcare, particularly in AI-powered pharmaceutical technology and services.
What's next for Korio?
With this latest infusion of capital, Korio is poised to enter a phase of aggressive enterprise scaling. The strategic roadmap likely includes the expansion of its engineering team to further refine its AI-driven insights and the broadening of its commercial footprint across international markets. As the company continues to integrate deeper into the pharmaceutical supply chain, the focus will remain on maintaining high-fidelity data integrity while scaling its platform to support larger, multi-site global trials.
The backing from specialized healthcare investors suggests a long-term commitment to building a dominant player in the digital health infrastructure space. Future growth will likely be driven by strategic partnerships with major pharmaceutical firms seeking to modernize their research operations, ensuring that Korio remains at the forefront of the digital revolution in clinical development.
